Natasha Loder
Showing 1–6 of 6 transcripts.
- The Economist9 min
Peptides are not a miracle drug | The Economist
Natasha Loder, Tim Cross, Jason Palmer
Driven by high-profile endorsements and internet culture, the unregulated global market for peptides bypasses clinical trials to offer performance-enhancing substances riddled with purity risks and unknown long-term health effects. Regulatory bodies in the United States and United Kingdom are attempting to address this crisis through compounding pharmacy oversight and vendor crackdowns, yet enforcement struggles against the speed of online sales and social media promotion. Experts warn that without rigorous scientific validation, the current environment prioritizes profit and self-experimentation over the biological safety required to distinguish beneficial compounds from dangerous contaminants.
- The Economist21 min
Rio brand: why Brazil is courting China
Jason Palmer, Rosie Bloor, Ana Lankes, Natasha Loder, James Francham
At the G20 summit in Rio de Janeiro, Brazilian President Luiz Inácio Lula da Silva criticized neoliberal globalization and proposed reforming international institutions while Brazil pivots economically and strategically toward China to offset tensions with an anticipated Trump administration. Concurrently, a Guy Foundation report warns that space travel induces accelerated aging by damaging astronaut mitochondria, suggesting that deep-space colonization may eventually require genetic engineering to overcome biological barriers. Finally, the United Kingdom's telecommunications infrastructure has deteriorated to rank among the worst in the developed world due to regulatory setbacks, insufficient investment, and planning restrictions, prompting a controversial proposed merger between Vodafone and 3 to alleviate capacity constraints.
- The Economist24 min
Hot shot: the wider promise of weight-loss jabs
Rosie Bloor, Natasha Loder, Simon Rabinovich, Alice Su
GLP-1 receptor agonists such as Zepbound and Wegovy have demonstrated significant cardiovascular protection independent of weight loss while sparking economic speculation regarding shifts in industries like aviation and insurance. Concurrently, robust US economic indicators including 3% GDP growth and low unemployment starkly contrast with depressed consumer sentiment driven by lingering inflation concerns and political polarization. Meanwhile, a tenfold surge in Chinese migration through the Darién Gap reflects a hybrid of political persecution and economic stagnation, marking the fastest-growing demographic group in the current US border crisis.
- The Economist22 min
America's next top-job model: our election forecast
Rosie Bloor, Jason Palmer, Dan Rosenheck, Natasha Loder, Caitlin Talbot
Recent polling indicates Donald Trump holds a 60% probability of winning the 2024 election despite legal convictions, as economic dissatisfaction drives a stable race in the Sunbelt states. Concurrently, global malaria progress has stalled due to drug resistance and funding gaps, prompting the rollout of the affordable R21 vaccine as a critical intervention tool. Meanwhile, the "tradwife" social media trend has garnered hundreds of millions of views by romanticizing domesticity, though labor statistics reveal this aesthetic remains largely performative rather than a mass workforce exodus.
- The Economist7 min
Covid-19: Can vaccines keep up with variants?
Driven by the Delta variant and potential mutations within immune-suppressed hosts, the pandemic persists as unchecked global transmission threatens to create vaccine-evading "omega" variants. Experts warn that while current vaccines remain effective against severe outcomes, the primary risk lies in uncontrolled spread leading to higher absolute death tolls and future immune evasion. To prevent this nightmare scenario, scientists advocate for proactive surveillance at human-animal interfaces and the development of rapid variant-specific vaccines alongside stricter laboratory and environmental security protocols.
- The Economist8 min
Covid-19 vaccines: what information can you trust?
Regulatory bodies and bioethicists are navigating complex challenges including the deployment of single-dose Johnson & Johnson vaccines, the strategic extension of mRNA dosing intervals to boost population immunity, and the ethical implications of mandatory vaccination or vaccine passports. While media outlets must carefully distinguish between chance adverse events and vaccine causation, experts emphasize that the rapid adaptability of mRNA platforms provides a robust foundation for updating shots against future viral mutations. Ultimately, governments favoring pragmatic public health measures over legal mandates are balancing rising hospitalization rates with the risk of fueling vaccine hesitancy among the public.